ClinicalTrials.gg
CompletedNCT00118703Updated Aug 21, 2017Results posted

Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis

A Phase 3 interventional study of GW685698X in Vasomotor Rhinitis and Rhinitis, Vasomotor, sponsored by GlaxoSmithKline. Completed at 59 sites in 7 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-08-21.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with vasomotor rhinitis (VMR).

02

Conditions studied

  • Vasomotor Rhinitis
  • Rhinitis, Vasomotor

Keywords

  • nonallergic rhinitis
  • GW685698X
  • VMR
  • vasomotor rhinitis
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be outpatients.
  • Diagnosis of VMR (vasomotor rhinitis).
  • Literate in English or native language.

Exclusion criteria

Exclusion criteria:

  • Significant concomitant medical condition.
  • Use or other allergy medications during the study.
  • Used tobacco products within the past year.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
350 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS)

    The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS was a rating of the severity of symptoms over the previous 12 hours and was performed in the morning (AM rTNSS) and evening (post meridian \[PM\] rTNSS). The daily rTNSS was the sum of two assessments. The Baseline daily rTNSS was defined as the average of the daily rTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline.

    Time frame: Baseline and up to Week 4

Secondary outcomes

  1. Mean Change From Baseline in Morning (AM) Pre-dose Instantaneous Total Nasal Symptom Scores (iTNSS)

    The morning pre-dose iTNSS was the sum of the individual symptom score for rhinorrhoea, nasal congestion and postnasal drip performed immediately prior to taking the daily dose which were scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The Baseline daily iTNSS was defined as the average of the daily iTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline value.

    Time frame: Baseline and up to Week 4

  2. Number of Participants Based on Overall Evaluation of Response to Therapy

    Participants were evaluated effectiveness of study medication for relieving non-allergic rhinitis symptoms over the entire treatment period. The overall evaluation of response to therapy was based on a 7-point categorical scale (1-7) where the participants rate their perception of the change or lack of change in their VMR symptoms at the end of the study. The 7 categories were: 1: significantly improved, 2: moderately improved, 3: mildly improved, 4: no change, 5: mildly worse, 6: moderately worse and 7: significantly worse. Effectiveness of study medication for relieving VMR symptoms over the entire treatment period.

    Time frame: Week 4 (Day 29) or Early Withdrawal

07

Results

Posted May 2, 2017

Participant flow

The actual dose delivered from the product was 27.5 micrograms (µg) /actuation, which is therefore proposed as the label claim rather than 25 µg/actuation. Based on this spray content assessment, the dose examined in this study was actually 110 µg rather than the 100 µg dose indicated in the protocol.

Participant flow — Overall Study
MilestonePlaceboFluticasone Furoate 110 µg QD
Started173174
Completed168165
Not completed59
Withdrew: Protocol violation10
Withdrew: Adverse event11
Withdrew: Participant took two different treatment01
Withdrew: Withdrawal by subject25
Withdrew: Lost to follow-up12

Outcome measures

PrimaryMean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS)

The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS was a rating of the severity of symptoms over the previous 12 hours and was performed in the morning (AM rTNSS) and evening (post meridian \[PM\] rTNSS). The daily rTNSS was the sum of two assessments. The Baseline daily rTNSS was defined as the average of the daily rTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline.

Time frame:
Baseline and up to Week 4
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS)
Score on a scalePlaceboFluticasone Furoate 110 µg QD
Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS)-2.11 ± 0.15-2.01 ± 0.15
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 µg QD · ANCOVA · p = 0.604 · Mean difference (final values): 0.094 · 95% CI -0.26 to 0.45The analysis method was adjusted for Baseline rTNSS, country, age, and gender, in addition to treatment effect.
SecondaryMean Change From Baseline in Morning (AM) Pre-dose Instantaneous Total Nasal Symptom Scores (iTNSS)

The morning pre-dose iTNSS was the sum of the individual symptom score for rhinorrhoea, nasal congestion and postnasal drip performed immediately prior to taking the daily dose which were scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The Baseline daily iTNSS was defined as the average of the daily iTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline value.

Time frame:
Baseline and up to Week 4
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in Morning (AM) Pre-dose Instantaneous Total Nasal Symptom Scores (iTNSS)
Score on a scalePlaceboFluticasone Furoate 110 µg QD
Mean Change From Baseline in Morning (AM) Pre-dose Instantaneous Total Nasal Symptom Scores (iTNSS)-1.65 ± 0.14-1.59 ± 0.14
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 µg QD · ANCOVA · p = 0.729 · Mean difference (final values): 0.061 · 95% CI -0.29 to 0.41The analysis method was adjusted for Baseline iTNSS, country, age, and gender, in addition to treatment effect.
SecondaryNumber of Participants Based on Overall Evaluation of Response to Therapy

Participants were evaluated effectiveness of study medication for relieving non-allergic rhinitis symptoms over the entire treatment period. The overall evaluation of response to therapy was based on a 7-point categorical scale (1-7) where the participants rate their perception of the change or lack of change in their VMR symptoms at the end of the study. The 7 categories were: 1: significantly improved, 2: moderately improved, 3: mildly improved, 4: no change, 5: mildly worse, 6: moderately worse and 7: significantly worse. Effectiveness of study medication for relieving VMR symptoms over the entire treatment period.

Time frame:
Week 4 (Day 29) or Early Withdrawal
Reported as:
Number · Participants
Number of Participants Based on Overall Evaluation of Response to Therapy
ParticipantsPlaceboFluticasone Furoate 110 µg QD
Significantly Improved2028
Moderately Improved3941
Mildly Improved4243
No Change6350
Mildly Worse34
Moderately Worse23
Significantly Worse32
Statistical analysis
  • Placebo vs Fluticasone Furoate 110 µg QD · Regression, Logistic · p = 0.064Overall evaluation of response to therapy was illustrated and analyzed using logistic regression adjusting for age, gender, investigator, and treatmen

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from on or after the randomization date (Up to Day 34).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/173 (0%)0/173 (0%)38/173 (22%)
Fluticasone Furoate 110 µg QD0/174 (0%)1/174 (0.6%)42/174 (24.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboFluticasone Furoate 110 µg QD
Nephrotic syndromeRenal and urinary disorders0/1731/174
Most frequent other events
Most frequent other events
EventPlaceboFluticasone Furoate 110 µg QD
HeadacheNervous system disorders16/17314/174
EpistaxisRespiratory, thoracic and mediastinal disorders5/17312/174
NasopharyngitisInfections and infestations10/17311/174
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders5/1734/174
Back painMusculoskeletal and connective tissue disorders4/1731/174
Upper respiratory tract infectionInfections and infestations4/1731/174
DiarrhoeaGastrointestinal disorders0/1734/174

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboFluticasone Furoate 110 µg QDTotal
Mean44 ± 14.7243.8 ± 15.4443.9 ± 15.06
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFluticasone Furoate 110 µg QDTotal
Female108124232
Male6550115
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboFluticasone Furoate 110 µg QDTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American7613
White164167331
More than one race112
Unknown or Not Reported000
08

Study locations

59 sites
  • GSK Investigational Site
    Birmingham, Alabama 35209, United States
  • GSK Investigational Site
    Phoenix, Arizona 85012, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Fresno, California 93720, United States
  • GSK Investigational Site
    Irvine, California 92618, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Paramount, California 90723, United States
  • GSK Investigational Site
    Sacramento, California 95819, United States
  • GSK Investigational Site
    San Francisco, California 94102, United States
  • GSK Investigational Site
    San Jose, California 95128, United States
  • GSK Investigational Site
    Walnut Creek, California 94598, United States
  • GSK Investigational Site
    Englewood, Colorado 80112, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Sarasota, Florida 34233, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Vero Beach, Florida 32960, United States
  • GSK Investigational Site
    Stockbridge, Georgia 30281, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Chicago, Illinois 60632, United States
  • GSK Investigational Site
    South Bend, Indiana 46617, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71105, United States
  • GSK Investigational Site
    Bethesda, Maryland 20814, United States
  • GSK Investigational Site
    Wheaton, Maryland 20902, United States
  • GSK Investigational Site
    North Dartmouth, Massachusetts 02747, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63141, United States
  • GSK Investigational Site
    Bricktown, New Jersey 8724, United States
  • GSK Investigational Site
    Skillman, New Jersey 08558, United States
  • GSK Investigational Site
    Ithaca, New York 14850, United States
  • GSK Investigational Site
    Rochester, New York 14618, United States
  • GSK Investigational Site
    Sylvania, Ohio 43560, United States
  • GSK Investigational Site
    Blue Bell, Pennsylvania 19422, United States
  • GSK Investigational Site
    Providence, Rhode Island 2906, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37421, United States
  • GSK Investigational Site
    Dallas, Texas 75231-4307, United States
  • GSK Investigational Site
    Dallas, Texas 75231, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    South Burlington, Vermont 05403, United States
  • GSK Investigational Site
    Winnipeg, Manitoba R3C 0N2, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8M 1K7, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1Y 4G2, Canada
  • GSK Investigational Site
    Trois Rivières, Quebec G8T 7A1, Canada
  • GSK Investigational Site
    Brno, 656 51, Czechia
  • GSK Investigational Site
    Pardubice, 532 03, Czechia
  • GSK Investigational Site
    Plzen, 301 00, Czechia
  • GSK Investigational Site
    Praha 5, 150 06, Czechia
  • GSK Investigational Site
    Weinheim, Baden-Wuerttemberg 69469, Germany
  • GSK Investigational Site
    Nuernberg, Bayern 90443, Germany
  • GSK Investigational Site
    Wiesbaden, Hessen 65187, Germany
  • GSK Investigational Site
    Berlin, 12163, Germany
  • GSK Investigational Site
    Berlin, 13125, Germany
  • GSK Investigational Site
    Berlin, 14057, Germany
  • GSK Investigational Site
    Oslo, N-0264, Norway
  • GSK Investigational Site
    Oslo, N-0594, Norway
  • GSK Investigational Site
    Ponce, 00716, Puerto Rico
  • GSK Investigational Site
    Bucharest, 022102, Romania
  • GSK Investigational Site
    Iasi, 700115, Romania
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Feb 2006 and a completion of Feb 2006. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 11 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2005
First posted
Jul 12, 2005
Start
Jul 1, 2005
Primary completionActual
Feb 1, 2006
CompletionActual
Feb 9, 2006
Results first posted
May 2, 2017
Last update
Aug 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00118703
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 12, 2005
Start date
Jul 1, 2005
Primary completion
Feb 1, 2006
Completion
Feb 9, 2006
Results posted
May 2, 2017
Last update
Aug 21, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone furoate

Start the discussion